U.S. markets closed

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
105.49-2.16 (-2.01%)
At close: 4:00PM EDT
105.49 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close107.65
Open107.65
Bid99.98 x 900
Ask175.00 x 800
Day's Range105.40 - 108.04
52 Week Range97.00 - 142.62
Volume106,025
Avg. Volume138,973
Market Cap1.75B
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-14.06
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est177.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
    GlobeNewswire

    Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

    WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences: 42nd Annual Goldman Sachs Global Healthcare Conference Fireside chat at 9:40 a.m. ET on Thursday, June 1

  • We're Interested To See How Madrigal Pharmaceuticals (NASDAQ:MDGL) Uses Its Cash Hoard To Grow
    Simply Wall St.

    We're Interested To See How Madrigal Pharmaceuticals (NASDAQ:MDGL) Uses Its Cash Hoard To Grow

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference
    GlobeNewswire

    Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference

    WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 pm ET. The fireside chat will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will be available for replay for 90 days. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients. For more information, visit www.madrigalpharma.com. Investor Contact:Alex Howarth, Madrigal Pharmaceuticals, Inc. IR@madrigalpharma.com